The Cepham Inc. research and development (R&D) team will present "Safety, Efficacy and Toxicological Evaluation of a Novel, Patented Anti-Diabetic Extract of Trigonella foenum-graceum Seed Extract (CR001810)" at the 53rd Annual Meeting of the Society of Toxicology on March 24 in Phoenix. The presentation marks the introduction of the abstract of a soon-to-be published study on the safety and efficacy of Fenfuro, a novel patented furostanolic saponins-enriched fenugreek (Trigonella foenum-graceum) extract from Cepham.
The unpublished study found that Fenfuro demonstrated a broad safety spectrum. The acute oral toxicology is greater than 5,000 mg/kg body weight in rats and mice. Fenfuro (150 mg/kg po) also reduced the plasma triglyceride level in type 2 diabetic rats by 22 percetn, 24.6 percent and 29 percent at 10-, 20- and 30 days of treatment, respectively. Fenfuro also exhibited significant hypoglycemic activty in the diabetic rats compared to insulin. No adverse events were noted.